AIG to sell more than $700 million worth of Corebridge Financial stock, less than a month after selling $1 billion
American International Group Inc. (AIG) said Friday that it will sell off another 35 million shares of Corebridge Financial Inc. (CRBG), but will remain a majority owner of the retirement services company. Corebridge's stock fell 2.5% in premarket trading, while AIG shares were still inactive. The shares AIG is selling, which represents about 5.6% of the shares outstanding, would be valued at about $736 million at Thursday's stock closing price of $21.03. The sale comes less than a month after AIG sold 50 million shares of Corebridge to raise $1.03 billion. Prior to Friday's announcement, AIG owned about 365.4 million Corebridge shares, or 57.5% of the shares outstanding, according to FactSet data. Corebridge separated from AIG in September 2022 through an initial public offering. Corebridge's stock has rallied 16.5% over the past three months through Thursday, while AIG shares have climbed 11.1% and the S&P 500 has tacked on 1.2%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-01-23 0625ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks